457 related articles for article (PubMed ID: 27626654)
1. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
2. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
3. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract][Full Text] [Related]
4. BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
Andrieu GP; Shafran JS; Smith CL; Belkina AC; Casey AN; Jafari N; Denis GV
Cancer Lett; 2019 Nov; 465():45-58. PubMed ID: 31473251
[TBL] [Abstract][Full Text] [Related]
5. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
[TBL] [Abstract][Full Text] [Related]
6. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
9. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
11. Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses.
Remke N; Bisht S; Oberbeck S; Nolting J; Brossart P
Cancer Immunol Immunother; 2021 Jan; 70(1):107-121. PubMed ID: 32651619
[TBL] [Abstract][Full Text] [Related]
12. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
13. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
18. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
20. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]